---
title: "BolaKang Vision Cloud's new drug application for the treatment of presbyopia lotion has been approved for clinical trials in the United States"
description: "BolaKang Vision Cloud announced that its U.S. registered subsidiary ADS USA has completed the review of the clinical trial application for the new drug CBT-199, and the application is now effective, a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276036456.md"
published_at: "2026-02-16T06:17:27.000Z"
---

# BolaKang Vision Cloud's new drug application for the treatment of presbyopia lotion has been approved for clinical trials in the United States

> BolaKang Vision Cloud announced that its U.S. registered subsidiary ADS USA has completed the review of the clinical trial application for the new drug CBT-199, and the application is now effective, allowing the clinical trial to proceed safely. CBT-199 is a novel topical ophthalmic emulsion for the treatment of presbyopia, which began the drug discovery process in China in 2023 and has undergone safety and tolerability assessments in preclinical animal studies. This progress marks an important milestone in the clinical development of CBT-199, and the group has been authorized to initiate Phase 2 clinical trials

Bokang Shiyun - B (02592.HK) announced that its U.S. registered subsidiary ADS USA has completed the review period for the new drug clinical trial application for CBT-199 submitted to the U.S. Food and Drug Administration on December 12 of last year. Since the U.S. FDA has not issued any clinical trial suspension orders, the new drug clinical trial application is now effective, and the clinical trial has been deemed safe to proceed. CBT-199 is a novel topical ocular emulsion for the treatment of presbyopia.

The group has commenced the drug discovery process for CBT-199 in the People's Republic of China in 2023. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, and these studies are expected to assist in future clinical trials.

The company believes that the clinical trial of CBT-199 being deemed safe to proceed marks a key milestone in the clinical development of CBT-199, and the group has officially been authorized to initiate Phase 2 clinical trials

### Related Stocks

- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US - Direxion S&P Biotech Bull 3X](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.AU - BlackRock, Inc.](https://longbridge.com/en/quote/IXJ.AU.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ascletis Pharma Unveils Promising Oral Amylin Agonist for Obesity Treatment | Ascletis Pharma Inc. has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical devel | [Link](https://longbridge.com/en/news/275522747.md) |
| Abbisko Therapeutics Doses First U.S. Patient in Global Phase I Study of Irpagratinib | Abbisko Therapeutics has successfully dosed the first U.S. patient in a global Phase I study of irpagratinib, an FGFR4 i | [Link](https://longbridge.com/en/news/275526780.md) |
| Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says | Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says | [Link](https://longbridge.com/en/news/275490601.md) |
| BUZZ-Nektar Therapeutics eases after boosted $400 mln share sale | Nektar Therapeuticsshares fell 5.6% premarket to $62.63 after a $400 million equity raise, selling approximately 6.9 mil | [Link](https://longbridge.com/en/news/275769952.md) |
| Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies | Ascletis Pharma Selects Oral Weight-Loss Drug for Further US Studies | [Link](https://longbridge.com/en/news/275537101.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.